biotech / news / / Gilead Sciences
Visceral leishmaniasis (VL) is the second deadliest parasitic disease after malaria.
Gilead renewed its five-year WHO partnership, donating over 400,000 AmBisome vials and $9.2 million.
KEY POINTS
- The expanded agreement newly includes Chad and Djibouti in its list of supported high-burden countries.
- Previous Gilead-WHO efforts reduced new VL cases by over 95% in Southeast Asia since 2005.
- In 2023, Bangladesh achieved WHO validation for VL elimination as a public health problem.
COMPANIES
Summarized by Newsio from Gilead Sciences. How we summarize →